{"title":"爱尔兰共和国脑膜炎球菌病:1995年。","authors":"I Fogarty, M T Cafferkey, A C Moloney","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Two hundred and nine culture confirmed cases of meningococcal disease were reported in the Republic of Ireland in 1995, using a new laboratory based surveillance system. The reported rate of 5.9/100000 population is one of the highest in western Europe, but the rate differed widely between regions. Fifty-three per cent of cases were female. Half of the cases occurred in four months (January, February, March, and December). Nineteen cases (9%) died. The highest age specific incidence was in infancy (under 1 year). Infections with serogroup B accounted for 105 cases (54%) and serogroup C 87 cases (45%). We estimate that up to 30% of cases of meningococcal disease may be preventable when conjugate meningococcal group C vaccines become available, but cost benefit analyses will be required to determine how they should be employed.</p>","PeriodicalId":77078,"journal":{"name":"Communicable disease report. CDR review","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1997-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meningococcal disease in the Republic of Ireland: 1995.\",\"authors\":\"I Fogarty, M T Cafferkey, A C Moloney\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Two hundred and nine culture confirmed cases of meningococcal disease were reported in the Republic of Ireland in 1995, using a new laboratory based surveillance system. The reported rate of 5.9/100000 population is one of the highest in western Europe, but the rate differed widely between regions. Fifty-three per cent of cases were female. Half of the cases occurred in four months (January, February, March, and December). Nineteen cases (9%) died. The highest age specific incidence was in infancy (under 1 year). Infections with serogroup B accounted for 105 cases (54%) and serogroup C 87 cases (45%). We estimate that up to 30% of cases of meningococcal disease may be preventable when conjugate meningococcal group C vaccines become available, but cost benefit analyses will be required to determine how they should be employed.</p>\",\"PeriodicalId\":77078,\"journal\":{\"name\":\"Communicable disease report. CDR review\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1997-01-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Communicable disease report. CDR review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communicable disease report. CDR review","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Meningococcal disease in the Republic of Ireland: 1995.
Two hundred and nine culture confirmed cases of meningococcal disease were reported in the Republic of Ireland in 1995, using a new laboratory based surveillance system. The reported rate of 5.9/100000 population is one of the highest in western Europe, but the rate differed widely between regions. Fifty-three per cent of cases were female. Half of the cases occurred in four months (January, February, March, and December). Nineteen cases (9%) died. The highest age specific incidence was in infancy (under 1 year). Infections with serogroup B accounted for 105 cases (54%) and serogroup C 87 cases (45%). We estimate that up to 30% of cases of meningococcal disease may be preventable when conjugate meningococcal group C vaccines become available, but cost benefit analyses will be required to determine how they should be employed.